These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

138 related items for PubMed ID: 7711675

  • 1. Interleukin-2 therapy after allogeneic bone marrow transplantation for acute myelocytic leukemia: studies in a relevant rat model for AML.
    Kloosterman TC, Martens AC, Osterwalder B, Hagenbeek A.
    Bone Marrow Transplant; 1994 Dec; 14(6):965-73. PubMed ID: 7711675
    [Abstract] [Full Text] [Related]

  • 2. Quantitative studies on graft-versus-leukemia after allogeneic bone marrow transplantation in rat models for acute myelocytic and lymphocytic leukemia.
    Kloosterman TC, Tielemans MJ, Martens AC, van Bekkum DW, Hagenbeek A.
    Bone Marrow Transplant; 1994 Jul; 14(1):15-22. PubMed ID: 7951103
    [Abstract] [Full Text] [Related]

  • 3. Graft-versus-leukemia in rat MHC-mismatched bone marrow transplantation is merely an allogeneic effect.
    Kloosterman TC, Martens AC, van Bekkum DW, Hagenbeek A.
    Bone Marrow Transplant; 1995 Apr; 15(4):583-90. PubMed ID: 7655385
    [Abstract] [Full Text] [Related]

  • 4. Influence of ultraviolet-B irradiation on engraftment, graft-versus-host disease and graft-versus-leukemia effect in a rat model for allogeneic bone marrow transplantation.
    Gowing H, Braakman E, Hagenbeek A, Lawler M, McCann SR, Pamphilon DH, Martens AC.
    Bone Marrow Transplant; 1998 Apr; 21(8):801-7. PubMed ID: 9603404
    [Abstract] [Full Text] [Related]

  • 5. A second prophylactic MHC-mismatched bone marrow transplantation protects against rat acute myeloid leukemia (BNML) without lethal graft-versus-host disease.
    Nestvold JM, Omdal BK, Dai KZ, Martens A, Benestad HB, Vaage JT, Rolstad B.
    Transplantation; 2008 Jan 15; 85(1):102-11. PubMed ID: 18192919
    [Abstract] [Full Text] [Related]

  • 6. Enhancement of GVL effect with rhIL-2 following BMT in a murine model for acute myeloid leukemia in SJL/J mice.
    Vourka-Karussis U, Karussis D, Ackerstein A, Slavin S.
    Exp Hematol; 1995 Mar 15; 23(3):196-201. PubMed ID: 7875238
    [Abstract] [Full Text] [Related]

  • 7. Alloreactivity and the predictive value of anti-recipient specific interleukin 2 producing helper T lymphocyte precursor frequencies for alloreactivity after bone marrow transplantation.
    Russell CA.
    Dan Med Bull; 2002 May 15; 49(2):89-108. PubMed ID: 12064093
    [Abstract] [Full Text] [Related]

  • 8. Allogeneic cell therapy for relapsed leukemia after bone marrow transplantation with donor peripheral blood lymphocytes.
    Slavin S, Naparstek E, Nagler A, Ackerstein A, Kapelushnik J, Or R.
    Exp Hematol; 1995 Dec 15; 23(14):1553-62. PubMed ID: 8542946
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Induction of graft versus leukemia effect in bone marrow transplantation: dosage and time schedule dependency of interleukin 2 therapy.
    Charak BS, Brynes RK, Katsuda S, Groshen S, Chen SC, Mazumder A.
    Cancer Res; 1991 Apr 15; 51(8):2015-20. PubMed ID: 2009520
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. [Hematopoietic stem cell transplantation for treatment of acute leukemia].
    Harada M.
    Gan To Kagaku Ryoho; 1999 Sep 15; 26(10):1387-95. PubMed ID: 10500524
    [Abstract] [Full Text] [Related]

  • 14. IL-2 inhibits early increases in serum gamma interferon levels associated with graft-versus-host-disease.
    Szebeni J, Wang MG, Pearson DA, Szot GL, Sykes M.
    Transplantation; 1994 Dec 27; 58(12):1385-93. PubMed ID: 7809932
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Allogeneic cell-mediated immunotherapy using donor lymphocytes for prevention of relapse in patients treated with allogeneic bone marrow transplantation for hematological malignancies.
    Naparstek E, Nagler A, Or R, Kapelushnik J, Slavin S.
    Clin Transpl; 1996 Dec 27; ():281-90. PubMed ID: 9286578
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.